I wrote about this fascinating work by @leahhouri.bsky.social, @leslievosshall.bsky.social et al for @nature.com:
I wrote about this fascinating work by @leahhouri.bsky.social, @leslievosshall.bsky.social et al for @nature.com:
Fighting mosquito-borne diseases... with more mosquitoes!
Loved working on this vid with @marilenharo.bsky.social for @nature.com 🧪
www.youtube.com/watch?v=-3Nc...
Fighting mosquito-borne diseases... with more mosquitoes!
Loved working on this vid with @marilenharo.bsky.social for @nature.com 🧪
www.youtube.com/watch?v=-3Nc...
A small pilot study suggests that liraglutide, a GLP-1 drug, might halve migraine frequency in people with obesity. The results are preliminary, but experts say they’re promising.
I wrote about it for @nature.com:
#Migraine #ObesityDrugs #GLP-1
A small pilot study suggests that liraglutide, a GLP-1 drug, might halve migraine frequency in people with obesity. The results are preliminary, but experts say they’re promising.
I wrote about it for @nature.com:
#Migraine #ObesityDrugs #GLP-1
That's because a new NIH policy has abruptly cut off billions to trials abroad. 🧪
That's because a new NIH policy has abruptly cut off billions to trials abroad. 🧪
Those that have used AI, more often than not didn't disclose it.
www.nature.com/articles/d41...
@nature.com
Those that have used AI, more often than not didn't disclose it.
www.nature.com/articles/d41...
@nature.com